Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease - PubMed (original) (raw)
. 1978 Dec;121(6):2213-9.
- PMID: 363941
Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease
S Izui et al. J Immunol. 1978 Dec.
Abstract
Early in life, mice of four kinds [NZB, (NZB X NZW)F1, MRL/1, and male BXSB] with autoimmune disease spontaneously produced far more (greater than 3 S.D.) anti-hapten antibody-forming cells in spleens and greater concentrations of anti-hapten antibodies in sera than immunologically normal strains of mice (AKR, BALB/c, C57BL/6, DBA/1-J, DBA/2J, LG/J, 129, NZW, and female BXSB). This increased nonspecific antibody production by the abnormal animals' B cells correlated well with the spontaneous development of anti-single-stranded DNA antibodies, but not with serum levels of the viral envelope glycoprotein, gp70. These results suggest that the spontaneous formation of autoantibodies in mice whose immunologic disorder is manifested by a lupus-like disease may result from polyclonal activation of B cells by endogenous or exogenous B cell activators.
Similar articles
- Resting B cells from New Zealand Black mice demonstrate a defect in apoptosis induction following surface IgM ligation.
Kozono Y, Kotzin BL, Holers VM. Kozono Y, et al. J Immunol. 1996 Jun 1;156(11):4498-503. J Immunol. 1996. PMID: 8666826 - Responses of B cells from autoimmune mice to IL-5.
Umland SP, Go NF, Cupp JE, Howard M. Umland SP, et al. J Immunol. 1989 Mar 1;142(5):1528-35. J Immunol. 1989. PMID: 2783944 - Immunologic and viral factors in autoimmune diseases.
Talal N. Talal N. Med Clin North Am. 1977 Mar;61(2):205-15. doi: 10.1016/s0025-7125(16)31327-x. Med Clin North Am. 1977. PMID: 192974 Review. No abstract available.
Cited by
- Loss of epigenetic modifications on the inactive X chromosome and sex-biased gene expression profiles in B cells from NZB/W F1 mice with lupus-like disease.
Syrett CM, Sierra I, Beethem ZT, Dubin AH, Anguera MC. Syrett CM, et al. J Autoimmun. 2020 Feb;107:102357. doi: 10.1016/j.jaut.2019.102357. Epub 2019 Nov 25. J Autoimmun. 2020. PMID: 31780316 Free PMC article. - Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.
Samotij D, Reich A. Samotij D, et al. Biomed Res Int. 2019 Jul 18;2019:8142368. doi: 10.1155/2019/8142368. eCollection 2019. Biomed Res Int. 2019. PMID: 31396534 Free PMC article. - Loss of an IgG plasma cell checkpoint in patients with lupus.
Suurmond J, Atisha-Fregoso Y, Marasco E, Barlev AN, Ahmed N, Calderon SA, Wong MY, Mackay MC, Aranow C, Diamond B. Suurmond J, et al. J Allergy Clin Immunol. 2019 Apr;143(4):1586-1597. doi: 10.1016/j.jaci.2018.10.041. Epub 2018 Nov 13. J Allergy Clin Immunol. 2019. PMID: 30439406 Free PMC article. - Multiple tolerance defects contribute to the breach of B cell tolerance in New Zealand Black chromosome 1 congenic mice.
Chang NH, Manion KP, Loh C, Pau E, Baglaenko Y, Wither JE. Chang NH, et al. PLoS One. 2017 Jun 19;12(6):e0179506. doi: 10.1371/journal.pone.0179506. eCollection 2017. PLoS One. 2017. PMID: 28628673 Free PMC article. - Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
Lenert A, Niewold TB, Lenert P. Lenert A, et al. Drug Des Devel Ther. 2017 Mar 13;11:747-757. doi: 10.2147/DDDT.S114552. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28331294 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources